Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. HGT is published 12 times per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The journal also publishes a wide range of reviews, commentaries and editorials. Human Gene Therapy is pleased to offer ESGCT members, affiliates, and meeting attendees a special rate for Open Access (OA) article publication. This member benefit, in collaboration with Liebert OA, offers authors 25% discount on OA page charges and colour art fees. OA may be ordered immediately upon article acceptance at this substantial savings.Publishing OA will make your article available to everyone, worldwide, in perpetuity for significantly increased readers, citations, and downloads. Additional benefits include fast-track publication, direct deposit of the article into PubMedCentral on your behalf, eliminating the 12-month embargo period, and a targeted email broadcast featuring your OA article. As an ESGCT member or affiliate you have the opportunity to make an impact in the human gene and cell therapy community with OA publication in Human Gene Therapy, HGT Methods, or HGT Clinical Development. Human Gene Therapy looks forward to receiving your impactful article contribution and we encourage members to recommend Human Gene Therapy to their library or institution to facilitate collaboration with colleagues. Please note that you will need active ESGCT membership to avail of this and other member benefits. Latest Impact Factor: * 4.510
*2019 Journal Citation Reports (Clarivate, 2020)
CiteScore™: 6.8
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!